Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy

Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy

Lung cancer is the most frequently diagnosed cancer type and the leading cause of cancer-related deaths worldwide. According to the last GLOBOCAN estimate of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC), lung cancer accounted for approximately 13%...

Full description

Bibliographic Details
Main Author: Tiziana Vavalà
Format: Article
Language:English
Published: European Medical Journal 2018-06-01
Series:European Medical Journal
Subjects:
checkpoint inhibitors
immunotherapy
lung cancer
non-small cell lung cancer (nsclc)
programmed death-1 (pd-1)
programmed death-ligand 1 (pd-l1)
Online Access:https://www.emjreviews.com/oncology/article/management-of-non-small-cell-lung-cancer-the-era-of-immunotherapy/

Internet

https://www.emjreviews.com/oncology/article/management-of-non-small-cell-lung-cancer-the-era-of-immunotherapy/

Similar Items